June 25, 2024

Tumor Ablation Market Size to Surpass USD 6.06 Bn by 2033

The global tumor ablation market size is expected to increase USD 6.06 billion by 2033 from USD 1.7 billion in 2023 with a CAGR of 13.60% between 2024 and 2033.
Key Takeaways

  • North America dominated the market while carrying 36% of the market share in 2023.
  • Asia Pacific is expected to witness the fastest rate of growth in the tumor ablation market during the forecast period.
  • By technology, the radio frequency ablation technology segment held the largest share of the tumor ablation market while carrying a of 34% share in 2023.
  • By technology, the microwave ablation technology segment is expected to grow at the fastest rate during the forecast period.
  • By treatment, the percutaneous ablation segment dominated the market with 56% market share in 2023.
Tumor Ablation Market Size 2024 to 2033

The tumor ablation market has witnessed a paradigm shift in cancer treatment methodologies, representing a revolutionary approach to combatting this formidable disease. Tumor ablation refers to the minimally invasive procedures designed to destroy cancerous cells or tissues, offering a promising alternative to traditional therapies. This market has gained substantial traction owing to its effectiveness, reduced side effects, and ability to treat various types of cancers. As technology continues to advance, the tumor ablation market is poised for remarkable growth, with a focus on improving patient outcomes and enhancing the overall quality of life.

Get a Sample: https://www.precedenceresearch.com/sample/3758

Growth Factors

Several key factors contribute to the robust growth of the tumor ablation market. Firstly, the rising incidence of cancer globally has necessitated the exploration of innovative and effective treatment modalities. Tumor ablation, with its targeted and minimally invasive nature, has become a preferred choice for both patients and healthcare providers. Additionally, advancements in imaging technologies have significantly improved the precision and accuracy of tumor ablation procedures, boosting its adoption rate.

Furthermore, the increasing elderly population, who are more susceptible to cancer, has driven the demand for less invasive treatments. The tumor ablation market is also benefiting from ongoing research and development activities, leading to the introduction of novel ablation techniques and devices. The integration of artificial intelligence in tumor ablation procedures is another growth factor, enhancing procedural planning and real-time monitoring.

Tumor Ablation Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 13.60%
Global Market Size in 2023 USD 1.7 Billion
Global Market Size by 2033 USD 6.06 Billion
U.S. Market Size in 2023 USD 430 Million
U.S. Market Size by 2033 USD 1,540 Million
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Technology, By Treatment, and By Application
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Recent Developments

  • In April 2023, Compal Electronics, a Taiwanese electronics company, unveiled a novel radiofrequency ablation (RFA) system designed for the percutaneous and intraoperative coagulation and ablation of soft tissue. This includes the partial or complete ablation of non-resectable liver lesions. Additionally, Compal Electronics introduced a bi-level ventilator targeting chronic obstructive pulmonary disease (COPD) and respiratory insufficiency resulting from central and/or mixed apneas.
  • In March 2022, Quantum Surgical, a company specializing in ablation devices and other medical technologies, obtained FDA approval for Epione, a ground-breaking interventional oncology robotics system designed specifically for minimally invasive liver cancer treatment. The Epione system from Quantum Surgical facilitates the planning and execution of minimally invasive ablation surgery, allowing it to be performed as an outpatient procedure. The system achieves this by deploying computer-guided needles through the skin to precisely target and eliminate tumors.
  • In September 2020, Boston Scientific Corporation disclosed the signing of an investment agreement that included an exclusive option to acquire Farapulse, Inc., a privately-held company engaged in the development of a pulsed field ablation (PFA) system for treating atrial fibrillation (AF) and other cardiac arrhythmias. The PFA system comprises a sheath, generator, and catheters, aiming to ablate heart tissue by creating a therapeutic electric field, contrasting with conventional thermal energy sources such as radiofrequency ablation or cryoablation.

Tumor Ablation Market Dynamics

Drivers:

A myriad of drivers propels the tumor ablation market forward. One of the primary drivers is the growing awareness among both patients and healthcare professionals about the advantages of minimally invasive procedures. Tumor ablation offers reduced recovery times, shorter hospital stays, and minimal damage to surrounding healthy tissues, contributing to an improved patient experience.

The market is also driven by the increasing investments in healthcare infrastructure, particularly in developing regions. As access to advanced medical facilities expands, more patients can benefit from tumor ablation therapies. Additionally, the collaboration between industry players and research institutions has led to the development of innovative ablation technologies, further driving market growth.

Restraints:

Despite the positive trajectory, the tumor ablation market faces certain restraints that warrant consideration. One significant challenge is the high cost associated with advanced ablation technologies. The initial capital investment and maintenance expenses for cutting-edge equipment can limit accessibility, particularly in resource-constrained healthcare settings.

Another restraint is the learning curve associated with adopting new technologies. Training healthcare professionals to proficiently perform tumor ablation procedures requires time and resources, potentially slowing down the widespread adoption of these techniques. Regulatory challenges and uncertainties also pose a restraint, necessitating a balance between ensuring patient safety and fostering innovation in the tumor ablation market.

Opportunities:

The tumor ablation market is rife with opportunities, driven by ongoing technological advancements and evolving treatment paradigms. The integration of robotics in tumor ablation procedures presents a promising avenue, offering enhanced precision and control during interventions. Furthermore, the expansion of the market into emerging economies presents a substantial opportunity for growth, with the potential to address the unmet medical needs of a large patient population.

Collaborations and partnerships between healthcare organizations, technology companies, and research institutions can unlock new opportunities for innovation and market expansion. Additionally, the increasing focus on personalized medicine opens avenues for the development of targeted tumor ablation therapies, tailoring treatments to individual patient profiles.

Read Also: U.S. Asthma Drugs Market Size to Cross USD 13.76 Bn by 2033

Tumor Ablation Market Companies

  • Boston Scientific Corporation (U.S.)
  • Medtronic (U.S.)
  • Olympus (Germany)
  • Stryker (U.S.)
  • Biotronik (Germany)
  • Merit Medical Systems. (Utah)
  • HealthTronics, Inc. (U.S.)
  • Insightec. (Israel)
  • AngioDynamics. (New York)
  • Integra LifeSciences (U.S.)
  • Bioventus LLC. (U.S.)
  • Ethicon Inc. (A Subsidiary of Johnson & Johnson) (U.S.)
  • EDAP TMS (Auvergne-Rhône-Alpes)
  • Sonablate Corp. (U.S.)
  • BVM Medical Limited (England)
  • Terumo Europe NV (Belgium)
  • IceCure Medical (Israel)

Segments Covered in the Report

By Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • Irreversible Electroporation Ablation
  • HIFU
  • Other ablation technologies

By Treatment

  • Surgical Ablation
  • Laparoscopic Ablation
  • Percutaneous Ablation

By Application

  • Kidney Cancer
  • Liver cancer
  • Breast cancer
  • Lung cancer
  • Prostate cancer
  • Other cancer

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/


Prathamesh

Leave a Reply

Your email address will not be published. Required fields are marked *